title: Acute procedural and cryoballoon characteristics from cryoablation of atrial fibrillation using the first- and second-generation cryoballoon: a retrospective comparative study with follow-up outcomes.
abstract: OBJECTIVE
  There is limited data available on the safety and efficacy of the second-generation cryoballoon (CB-2) for cryoablation of atrial fibrillation (Cryo-AF). We evaluated the procedural, biophysical, and clinical outcomes of Cryo-AF in a large patient cohort using CB-2 as compared with the first-generation cryoballoon (CB-1).
  
  
  METHODS
  Three-hundred and forty consecutive patients undergoing Cryo-AF with CB-1 (n = 140) and CB-2 (n = 200) were retrospectively evaluated.
  
  
  RESULTS
  Paroxysmal AF was more prevalent in CB-1 (86%) versus CB-2 (72%) (p = 0.001). During Cryo-AF, the mean balloon temperature was lower with CB-2 at 30 s (8 versus -4°C; p < 0.001) and 60 s (-26 versus -32°C; p < 0.001) with equivalent nadir temperatures (both at -50°C; p = 0.542). With CB-2, time-to-nadir temperature was shorter (232 versus 209 s; p < 0.001) and thaw times were longer (47 versus 53 s; p < 0.001). Acute pulmonary vein (PV) isolation rate was higher with CB-2 (92 versus 98%; p = 0.036) despite reduced cryoablation time (61 versus 47 min; p < 0.001) and freeze area-under-the-curve (-155,044 versus -116,740 s°C; p < 0.001). With CB-2, procedure time (209 versus 154 min; p < 0.001) and fluoroscopy time (42 versus 27 min; p < 0.001) were shorter, with similar acute/long-term adverse events (AEs) and freedom from AF at 6, 9, and 12 months (89, 86, and 82%) during 16 ± 8 months of follow-up. However, CB-2 was associated with lower PV reconnection rates at redo ablation (30 versus 13%; p = 0.037).
  
  
  CONCLUSIONS
  With CB-2, acute and long-term PV isolation rates were higher despite shorter ablations, faster balloon cooling, and longer thaw times, with similar AE rates and freedom from AF.
authors.affiliation: Regional Cardiology Associates, 3941 J Street, Suite #350, Sacramento, CA, 95819, USA, aaryana@rcamd.com.
authors.forename: Arash
authors.initials: A
authors.lastname: Aryana
authors.forename: Shemsa
authors.initials: S
authors.lastname: Morkoch
authors.forename: Sean
authors.initials: S
authors.lastname: Bailey
authors.forename: Hae W
authors.initials: HW
authors.lastname: Lim
authors.forename: Rahmani
authors.initials: R
authors.lastname: Sara
authors.forename: André
authors.initials: A
authors.lastname: d'Avila
authors.forename: P Gearoid
authors.initials: PG
authors.lastname: O'Neill
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D015331:Cohort Studies; D003452:Cryosurgery / Q000295:instrumentation / Q000379:methods*; D004562:Electrocardiography / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D061214:Patient Safety; D011667:Pulmonary Veins / Q000601:surgery*; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome